Genomic Health announces positive topline results for prostate cancer test Genomic Health announced positive results from a large clinical validation study of its biopsy-based prostate cancer test. The study, performed in collaboration with leading prostate cancer researchers at the University of California, met its primary endpoint by demonstrating that the multi-gene Oncotype DX(R) Genomic Prostate Score, assessed in prostate needle biopsy tumor tissue, has been prospectively validated as a predictor of adverse pathology for patients with early-stage prostate cancer. UCSF and Genomic Health plan to submit complete data from this study for presentation at the 2013 ASCO Genitourinary Cancers Symposium in February. Based on these results, Genomic Health is completing the necessary work in its Clinical Reference Laboratory to make the Oncotype DX prostate cancer test available to physicians and patients in the first half of 2013.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.